Cargando…
Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?
The rapid emergence of COVID-19 has sent shockwaves through healthcare systems globally, with cancer patients at increased risk. The interplay of the virus and host immune system has been implicated in the development of ARDS. Immunotherapy agents have the potential to adversely potentiate this phen...
Autores principales: | Pickles, Oliver J., Lee, Lennard Y. W., Starkey, Thomas, Freeman-Mills, Luke, Olsson-Brown, Anna, Cheng, Vinton, Hughes, Daniel J., Lee, Alvin, Purshouse, Karin, Middleton, Gary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296191/ https://www.ncbi.nlm.nih.gov/pubmed/32546835 http://dx.doi.org/10.1038/s41416-020-0930-7 |
Ejemplares similares
-
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
por: O’Donnell, Jake S., et al.
Publicado: (2016) -
Breaking barriers for glioblastoma with a path to enhanced drug delivery
por: Noorani, Imran, et al.
Publicado: (2023) -
Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach
por: Khan, Zia, et al.
Publicado: (2019) -
Proton pump inhibitors and adverse kidney outcomes during immune checkpoint blockade: time to sound the alarm?
por: Tan, Hui Zhuan, et al.
Publicado: (2023) -
IL-6 blockade for COVID-19: a global scientific call to arms
por: Murthy, Srinivas, et al.
Publicado: (2021)